¡Ya estamos en ! Descubre más

Shockwave Medical, Inc. Common Stock

SWAV

Capitalización de mercado USD 12.6 mil M

Excluida de cotización

SWAV dejó de cotizar en bolsa el 30 de mayo de 2024.

Volver al ranking

Acerca de: Shockwave Medical Inc is a medical device company focused on developing and commercializing novel technologies that transform the care of patients with cardiovascular disease. It establishes a new standard of care for the treatment of calcified cardiovascular disease ("atherosclerosis") through differentiated and proprietary local delivery of sonic pressure waves, which refer to as intravascular lithotripsy ("IVL"). Its IVL technology is a minimally invasive, easy-to-use, and safe way to improve outcomes for patients with calcified cardiovascular disease also IVL catheters enables delivery of IVL therapy to diseased vasculature throughout the body for calcium modification.

Empleados: 1,468

Atención médica Instrumentos y suministros médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 0%

Negativo 0%

J&J's $13 billion bid for Shockwave turns to Wall Street for funding

Johnson & Johnson JNJ, +0.29% rolled out a four-part bond on Monday to help fund its planned $13 billion acquisition of Shockwave Medical, underscoring how the Federal Reserve's rate hikes haven't dulled the appetite on Wall Street for deal-making.

SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Shockwave will receive $335.00 in cash for each share of Shockwave that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV

Zacks Investment Research

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

Zacks Investment Research

Shockwave Medical (SWAV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Shockwave Medical (SWAV) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research

Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates

Shockwave Medical (SWAV) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.03 per share a year ago.

Shockwave Medical Reports First Quarter 2024 Financial Results

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

Shockwave Medical Reports First Quarter 2024 Financial Results

Zacks Investment Research

Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research

Why the Market Dipped But Shockwave Medical (SWAV) Gained Today

In the latest trading session, Shockwave Medical (SWAV) closed at $328.99, marking a +0.04% move from the previous day.

Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research

Shockwave Medical (SWAV) Advances While Market Declines: Some Information for Investors

Shockwave Medical (SWAV) concluded the recent trading session at $329, signifying a +0.45% move from its prior day's close.

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™